For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...

La farmacéutica española Grifols SA está en conversaciones con bancos para refinanciar bonos que vencen el próximo año y ...

The Spanish pharmaceutical company said it considered Brookfield’s offer of 10.50 euros a share undervalued the company and ...

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...